As the rationale for targeting HDAC6 for the treatment of tauopathies is based on elevating tau acetylation on KXGS motifs, it should be mentioned that recent reports have suggested a pathogenic role for tau acetylation in disease (14,22). Here, HDAC6 is linked to tauopathy.